IL-1 receptor antagonist ameliorates inflammasome-dependent inflammation in murine and human cystic fibrosis
Rossana G. Iannitti(Fidia Farmaceutici (Italy)), Luigina Romani(University of Perugia), Marilena Pariano(University of Perugia), Vincenzo Nicola Talesa(University of Perugia), Fabio Majo(Bambino Gesù Children's Hospital), Gabriella Ricciotti(Bambino Gesù Children's Hospital), Cristina Massi-Benedetti(University of Perugia), Charles A. Dinarello(University of Colorado Anschutz Medical Campus), V. Lucidi(Bambino Gesù Children's Hospital), Luigi Ratclif, Helmut Ellemunter(Innsbruck Medical University), Maria Chiara Russo(University of Milan), Carla Colombo(University of Milan), Valerio Napolioni(Università di Camerino), Lisa Cariani(University of Milan), Matteo Puccetti(University of Perugia), Cornelia Lass‐Flörl(Innsbruck Medical University), Antonella De Luca(University of Perugia), Frank L. van de Veerdonk(Radboud University Nijmegen), Claudia Galosi(University of Perugia), Luigi Porcaro(University of Milan), Vasileios Oikonomou(National Institutes of Health), Monica Borghi(University of Perugia), Ersilia Fiscarelli(Bambino Gesù Children's Hospital)
Cited by 232
Related Papers
Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19
|JAMA|2020|884
Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome
|Critical Care Medicine|2015|858
Differential requirement for the activation of the inflammasome for processing and release of IL-1β in monocytes and macrophages
|Blood|2008|777
Immune defence against Candida fungal infections
|Nature reviews. Immunology|2015|643